S. O. Schönland: Fortschritte in der Diagnostik und Therapie der Amyloidosen. In: Deutsches Ärzteblatt. Band103, Nr.34–35, 2006, S.2237 (aerzteblatt.de [PDF]).
A Phase II Open-label Randomized Study of Dietary Supplement With Epigallocatechin Gallate (EGCG) to Improve Cardiac Dysfunction in Patients With AL Amyloidosis Who do Not Require Chemotherapy (EpiCardiAL).ClinicalTrials.gov.
Bouke P.C. Hazenberg: Amyloidosis: a clinical overview. Band39, Nr.2, Mai 2013, S.323–345, doi:10.1016/j.rdc.2013.02.012 (rug.nl [PDF; abgerufen am 8. September 2019]).
Morie A. Gertz, Merrill D. Benson, Peter J. Dyck, Martha Grogan, Terresa Coelho: Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis. In: Journal of the American College of Cardiology. Band66, Nr.21, Dezember 2015, S.2451–2466, doi:10.1016/j.jacc.2015.09.075.
Julian D. Gillmore, Daniel P. Judge, Francesco Cappelli, Marianna Fontana, et al., für die ATTRibute-CM-Forschungsgruppe: Efficacy and Safety of Acoramidis in Transthyretin Amyloid CardiomyopathyNew England Journal of Medicine 2024, Band 390, Ausgabe 2 vom 11. Januar 2024, Seiten 132–142, DOI: 10.1056/NEJMoa2305434
Yukio Ando, Teresa Coelho, John L Berk, Márcia Waddington Cruz, Bo-Göran Ericzon: Guideline of transthyretin-related hereditary amyloidosis for clinicians. In: Orphanet Journal of Rare Diseases. Band8, 20. Februar 2013, S.31, doi:10.1186/1750-1172-8-31, PMID 23425518, PMC 3584981 (freier Volltext).
David Adams, Alejandra Gonzalez-Duarte, William D. O’Riordan, Chih-Chao Yang, Mitsuharu Ueda: Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. In: New England Journal of Medicine. Band379, Nr.1, 5. Juli 2018, S.11–21, doi:10.1056/NEJMoa1716153.
Mathew S. Maurer, Jeffrey H. Schwartz, Balarama Gundapaneni, Perry M. Elliott, Giampaolo Merlini: Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. In: New England Journal of Medicine. Band379, Nr.11, 13. September 2018, S.1007–1016, doi:10.1056/NEJMoa1805689.
Bollee, Guillaume et al.: Presentation and Outcome of Patients with Systemic Amyloidosis Undergoing Dialysis. In: Clin J Am Soc Nephrol. Band3, Nr.2, 2008, S.375–381, doi:10.2215/CJN.02470607.
L. M. Dember u. a.: Eprodisate for the Treatment of Renal Disease in AA Amyloidosis. In: N Engl J Med. Band356, Nr.23, 2007, S.2349–2360, doi:10.1056/NEJMoa065644, PMID 17554116.
Derliz Mereles, Sebastian J. Buss, Stefan E. Hardt, Werner Hunstein, Hugo A. Katus: Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis. In: Clinical Research in Cardiology. Band99, Nr.8, 2010, S.483–490, doi:10.1007/s00392-010-0142-x.
Jan Bieschke, Jenny Russ, Ralf P. Friedrich, Dagmar E. Ehrnhoefer, Heike Wobst, Katja Neugebauer, Erich E. Wanker: EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity. In: Proceedings of the National Academy of Sciences. Band107, Nr.17, 2010, S.7710–7715, doi:10.1073/pnas.0910723107.
Yukio Ando, Teresa Coelho, John L Berk, Márcia Waddington Cruz, Bo-Göran Ericzon: Guideline of transthyretin-related hereditary amyloidosis for clinicians. In: Orphanet Journal of Rare Diseases. Band8, 20. Februar 2013, S.31, doi:10.1186/1750-1172-8-31, PMID 23425518, PMC 3584981 (freier Volltext).
L. M. Dember u. a.: Eprodisate for the Treatment of Renal Disease in AA Amyloidosis. In: N Engl J Med. Band356, Nr.23, 2007, S.2349–2360, doi:10.1056/NEJMoa065644, PMID 17554116.
rug.nl
pure.rug.nl
Bouke P.C. Hazenberg: Amyloidosis: a clinical overview. Band39, Nr.2, Mai 2013, S.323–345, doi:10.1016/j.rdc.2013.02.012 (rug.nl [PDF; abgerufen am 8. September 2019]).
